A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized ...

Scientists have discovered that the internal shape of tiny drug-delivery particles—called lipid nanoparticles—has a big ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...

The gene that triggers the most aggressive childhood cancer, neuroblastoma, has been discovered. The result, marking a step ...

Scientists at The University of Texas at Arlington have identified a new enzyme that can be “turned off” to help the body ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong decline in Verve’s share price amid skepticism over ...

The first testing centre will be operated by SingHealth and located at the National Heart Centre. Read more at ...